Os01g0833700 Antibody

What computational approaches are currently used for antibody design?

Antibody design has evolved to incorporate several computational approaches, each with distinct strengths and applications:

Physics-based approaches model biological systems by accounting for protein flexibility, explicit solvents, co-factors, and entropic effects. These methods provide energy-based metrics but often show low correlation with experimentally measured binding affinities. They also face challenges including high computational costs and difficulties in automation, limiting their utility for large-scale affinity predictions .

Graph-based methods represent antibody structures as graphs, where nodes correspond to residues or atoms, and edges capture spatial relationships. This approach enables the co-design of sequences and structures while respecting the underlying geometry of antibodies. For example, some methods propose iterative approaches to simultaneously design sequences and structures of CDRs in an autoregressive manner, while others use hierarchical message-passing networks that leverage epitope information to guide the design process .

Diffusion-based models generate new sequences and/or structures by simulating a process that progressively refines noisy input into coherent output. These models have proven effective due to their ability to handle geometric and structural constraints while capturing intricate dependencies in complex biological systems over multiple iterations. Examples include DiffAb, which integrates residue types, atom coordinates, and orientations to generate antigen-specific CDRs, and AbDiffuser, which incorporates domain-specific knowledge and physics-based constraints .

Large Language Model (LLM)-style approaches have also emerged as powerful tools for antibody design, leveraging vast amounts of sequence data to learn patterns and relationships in antibody structure and function .

How are computationally designed antibodies experimentally validated?

Experimental validation of computationally designed antibodies typically involves multiple stages and can be performed across different laboratories to ensure reproducibility. The validation process generally includes:

Expression and purification: Variable region sequences are cloned into appropriate backbones (e.g., IgG1) and expressed in mammalian cells. The antibodies are then purified, typically via Protein A affinity resin, to obtain sufficient quantities for characterization .

Biophysical characterization: Multiple parameters are assessed, including:

• Expression yield (titer), measured in mg/L

• Purity and monomer content (%) after purification

• Thermal stability (melting temperature/Tm)

• Hydrophobicity

• Self-association propensity

• Non-specific binding

These metrics are often compared against well-characterized control antibodies, such as marketed therapeutic antibodies or standards like trastuzumab or NISTmAb. For instance, in one study, 51 in-silico generated antibodies were analyzed by two independent laboratories, with comprehensive assessments of their biophysical properties compared to 100 marketed or clinical-stage antibodies .

Cross-laboratory validation: To ensure robustness, validation can be performed by independent laboratories using different methodologies. For example, in the study described in search result , two separate labs (referred to as Lab I and Lab II) independently assessed the performance of computationally generated antibodies, with no exchange of materials between them .

What metrics are used to evaluate antibody performance and developability?

Antibody performance and developability are evaluated using a combination of computational and experimental metrics:

Computational metrics:

• Log-likelihood scores from generative models, which have been shown to correlate strongly with experimentally measured binding affinities

• Predicted binding affinity changes (ΔΔG) calculated using deep learning models

• Humanness scores, which assess how closely an antibody sequence resembles human antibody sequences

• Medicine-likeness, which evaluates how similar an antibody's properties are to those of marketed antibody therapeutics

Experimental metrics:

• Production metrics:

  • Expression yield/titer (mg/L)

  • Purity after purification (%)

  • Monomer content (%)

• Stability metrics:

  • Thermal stability (Tm in °C), particularly of the Fab region

  • Aggregation propensity

• Interaction metrics:

  • Hydrophobicity

  • Poly-specificity (non-specific binding)

  • Self-association propensity

  • Binding affinity to target antigens

The table below shows experimental metrics for in-silico generated antibodies compared to trastuzumab as a control:

Note: PSP measures poly-specificity (non-specific binding) and CS-SINS measures self-association propensity .

How does deep learning contribute to antibody engineering?

Deep learning has transformed antibody engineering by enabling several key capabilities:

Generation of novel sequences: Deep learning models can generate large libraries of novel antibody sequences with desirable properties. For instance, researchers have used generative adversarial networks (GANs) to create 100,000 variable region sequences of antigen-agnostic human antibodies that recapitulate the intrinsic sequence, structural, and physicochemical properties of well-performing human antibodies .

Affinity prediction and optimization: Deep learning models trained on antibody-antigen complex structures and binding affinity data can predict changes in binding affinity due to amino acid substitutions, guiding the optimization process. These models extract interresidue interaction features and make predictions of ΔΔG values for single or multiple mutations .

Multi-objective optimization: Deep learning enables optimization toward multiple objectives simultaneously, such as improving binding to multiple variants of an antigen. Through iterative optimization of CDR regions guided by deep learning predictions, researchers have achieved expanded antibody breadth and improved potency by approximately 10- to 600-fold against SARS-CoV-2 variants .

Structure prediction and evaluation: Deep learning models, particularly geometric neural networks, can effectively model the structural impact of mutations and predict their effects on antibody-antigen interactions. Some approaches simulate in silico ensembles of predicted complex structures to obtain robust estimations of free energy changes .

Developability assessment: Deep learning models can be trained to predict various developability attributes, helping to filter or prioritize antibody candidates with favorable properties such as high expression, thermal stability, and low aggregation propensity .

How do different generative models compare for antibody design?

Generative models for antibody design have been rigorously evaluated using diverse real-world datasets to assess their relative performance:

LLM-style models leverage the power of attention mechanisms and large-scale pretraining to capture complex patterns in antibody sequences. These models can generate diverse sequences and have shown promise in preserving structural constraints implicit in the training data .

Diffusion-based models, such as DiffAb and AbDiffuser, have demonstrated particular strength in handling geometric constraints and structural information. These models progressively refine noisy inputs into coherent antibody designs through multiple denoising steps. A key advantage is their ability to simultaneously model sequence and structure, ensuring that generated antibodies maintain proper folding and spatial relationships between residues .

Graph-based approaches, like those proposed by Jin et al., excel at representing the geometric structure of antibody regions. By treating antibodies as graphs with nodes (residues/atoms) and edges (spatial relationships), these models can effectively co-design sequences and structures while respecting underlying geometry. This is particularly valuable for designing complementarity-determining regions (CDRs) that must fit specific epitopes .

Comparative benchmarks have shown that log-likelihood scores from these generative models correlate strongly with experimentally measured binding affinities, positioning log-likelihood as a reliable metric for ranking antibody sequence designs. Furthermore, scaling up diffusion-based generative models by training on large and diverse synthetic datasets has significantly enhanced their ability to predict and score binding affinities, outperforming existing models in terms of correlation with experimentally measured affinities .

The choice between these approaches depends on specific design goals, computational resources, and whether the focus is primarily on sequence generation, structure prediction, or both.

What methodological approaches are used to predict binding affinity changes in antibody-antigen interactions?

Predicting binding affinity changes (ΔΔG) in antibody-antigen interactions employs several sophisticated methodological approaches:

Geometric neural networks: These networks effectively extract interresidue interaction features and predict changes in binding affinity due to amino acid substitutions. Unlike traditional deep learning approaches, geometric neural networks specifically account for the 3D spatial relationships between residues in the antibody-antigen complex .

Ensemble methods: To improve prediction robustness, ensemble approaches combine multiple computational methods. For example, researchers have combined their deep learning models with other methods like Rosetta and GeoPPI to evaluate single and higher-order mutations. This approach helps mitigate the limitations of any single method and provides more reliable predictions .

In silico structural ensembles: To account for structural flexibility and uncertainty, some approaches simulate ensembles of predicted complex structures with CDR mutations. This provides a more robust estimation of free energy changes compared to using a single static structure .

Benchmarking against experimental data: Prediction methods are typically benchmarked against experimental binding data. For instance, one study used datasets such as SKEMPI and an additional subset of multipoint mutations (M1707) to validate their model's performance. The researchers found that their model achieved moderate to high correlation with experimental binding data and outperformed existing state-of-the-art methods like GeoPPI .

Multi-point mutation prediction: Advanced methods can predict the effects of not just single mutations but also combinations of mutations. This is particularly valuable for antibody optimization, where multiple CDR residues often need to be modified simultaneously to achieve desired improvements in binding affinity and specificity .

How can researchers balance multiple optimization objectives in antibody engineering?

Balancing multiple optimization objectives in antibody engineering requires sophisticated approaches that consider various, sometimes competing, properties:

Multi-objective optimization frameworks: Deep learning models can be designed to simultaneously optimize for multiple objectives. For instance, researchers have developed approaches to improve both binding affinity and breadth against multiple variants of an antigen. This involves defining appropriate objective functions that weight different goals according to their relative importance .

Iterative optimization with experimental feedback: Rather than attempting to optimize all objectives at once, researchers often employ iterative approaches where computational predictions guide experimental testing, and experimental results inform subsequent rounds of computational design. For example, in optimizing antibodies against SARS-CoV-2, researchers conducted multiple rounds of optimization, starting with single mutations and progressively combining beneficial mutations into double and triple mutants .

Pareto optimization: When objectives conflict (e.g., improving binding might decrease stability), Pareto optimization identifies solutions where no objective can be improved without worsening another. This generates a frontier of optimal trade-offs from which researchers can select candidates based on their specific priorities .

Ensemble prediction methods: Combining multiple computational methods helps provide more robust predictions across different objectives. For instance, researchers have combined geometric neural networks with traditional methods like Rosetta to better predict both binding affinity and structural stability .

Balancing binding and developability: While optimizing binding affinity is often a primary goal, maintaining good developability characteristics is equally important. Researchers can incorporate developability filters into their workflows, screening candidates for properties like expression yield, thermal stability, and low aggregation potential. For example, in one study, 51 in-silico generated antibodies were selected based on having >90th percentile medicine-likeness and >90% humanness before experimental validation .

How are antibody designs validated across multiple independent laboratories?

Cross-laboratory validation of antibody designs is a critical step in ensuring the robustness and reproducibility of computational design approaches. The process typically involves:

Independent expression and purification: Each laboratory independently expresses and purifies the designed antibodies using their established protocols. For example, in the study described in search result , two separate laboratories (Lab I and Lab II) expressed and purified the same set of in-silico generated antibody sequences without exchanging materials between them .

Standardized control antibodies: Well-characterized control antibodies are included in the validation process to provide benchmarks. Lab I compared the in-silico generated antibodies with a set of 100 marketed or clinical-stage antibodies, while Lab II used approved antibodies known to show desirable and poor developability attributes, including trastuzumab as a primary control .

Complementary assessment approaches: Different laboratories may use different but complementary assessment methods. For instance, Lab I in the referenced study conducted automated small-scale transient transfection, Protein A affinity purification, and biophysical characterization, while Lab II applied additional selection criteria and conducted its own set of experiments .

Comparative analysis of results: Results from different laboratories are compared to identify consistent patterns and potential discrepancies. In the example study, both laboratories consistently found that the in-silico generated antibodies exhibited good expression, high monomer content, and thermal stability along with low hydrophobicity, self-association, and non-specific binding .

Statistical validation: Statistical methods are applied to determine the significance of observed differences between designed antibodies and controls. For example, Lab I conducted statistical analyses comparing the distributions of titer, purity, thermal stability, and hydrophobicity between the in-silico generated antibodies and existing therapeutic antibodies .

This multi-laboratory validation approach helps establish confidence in the performance of computationally designed antibodies and identifies any potential limitations or inconsistencies in the design methodology.

How can deep learning models be scaled to improve antibody design accuracy?

Scaling deep learning models for improved antibody design accuracy involves several strategic approaches:

Expanding training datasets: Larger and more diverse training datasets significantly enhance model performance. Researchers have scaled up diffusion-based generative models by training them on extensive synthetic datasets, which significantly improved their ability to predict and score binding affinities. These scaled models have outperformed existing models in terms of correlation with experimentally measured affinities .

Architectural improvements: Advanced neural network architectures, particularly those designed to capture geometric relationships in protein structures, provide better performance for antibody design tasks. Geometric neural networks that effectively extract interresidue interaction features have shown superior performance in predicting changes in binding affinity due to amino acid substitutions .

Ensemble methods: Combining multiple computational approaches can improve prediction robustness. Researchers have created ensemble methods that integrate their deep learning models with other methods like Rosetta and GeoPPI to evaluate mutations more reliably .

Transfer learning: Pre-training models on large protein datasets before fine-tuning on antibody-specific data can improve performance, especially when antibody-specific data is limited .

Multi-objective training: Training models to simultaneously predict multiple properties (e.g., binding affinity, stability, developability) enables more holistic optimization. This approach helps create antibodies that not only bind their targets with high affinity but also possess favorable biophysical properties .

Computational scaling: Leveraging high-performance computing resources allows training on larger datasets, using more complex model architectures, and performing more extensive validation. Some studies have used simulation ensembles of predicted complex structures with CDR mutations to obtain robust estimations of free energy changes, which would be computationally intensive without appropriate scaling .

Through these scaling approaches, researchers have been able to significantly improve the accuracy and reliability of deep learning models for antibody design, leading to the successful generation of high-quality antibodies with desirable properties.